Breaking News, Promotions & Moves

bluebird bio Appoints O. James Sterling CFO

Mr. Sterling succeeds Chris Krawtschuk, who joined bluebird bio as chief financial officer in 2022.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

bluebird bio, Inc. has appointed O. James Sterling chief financial officer, effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease.   Mr. Sterling was previously managing partner at Renwick Capital LLC, and managing director at investment banks Brock Capital Group LLC and Aleutian Capital Group. He also serves as a board director for a fund managed by Star Mountain Capital. M...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters